[go: up one dir, main page]

KR970704436A - 항종양제로서 유용한 테르페노이딕 유도체 (사르코딕타인) (terpenoidic derivatives (sarcodictyins) useful as antitumor agents) - Google Patents

항종양제로서 유용한 테르페노이딕 유도체 (사르코딕타인) (terpenoidic derivatives (sarcodictyins) useful as antitumor agents)

Info

Publication number
KR970704436A
KR970704436A KR1019970700287A KR19970700287A KR970704436A KR 970704436 A KR970704436 A KR 970704436A KR 1019970700287 A KR1019970700287 A KR 1019970700287A KR 19970700287 A KR19970700287 A KR 19970700287A KR 970704436 A KR970704436 A KR 970704436A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
treatment
compound according
composition according
octahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019970700287A
Other languages
English (en)
Other versions
KR100420018B1 (ko
Inventor
카를로 바티스티니
마리나 시오메이
프란세스코 피에트라
미쉘 담브로시오
안토니오 구에리에로
Original Assignee
페라리오 비토리노
파마시아 앤드 업존 에스. 피. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 페라리오 비토리노, 파마시아 앤드 업존 에스. 피. 에이. filed Critical 페라리오 비토리노
Publication of KR970704436A publication Critical patent/KR970704436A/ko
Application granted granted Critical
Publication of KR100420018B1 publication Critical patent/KR100420018B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

본 발명은 치료제로 사용되는 사르코딕타인으로서, 당분야에 공지된 테르페노이딕 유도체, 및 이들을 함유하는 약제학적 조성물에 관한 것이다.
특히,사르코틱타인은 인간 또는 동물의 암 치료에서 항종양 치료제로서 유용하게 사용될수 있다.

Description

항종양제로서 유용한 테르페노이딕 유도체(사르코딕타인)(TERPENOIDIC DERIVATIVES (SARCODICTYINS) USEFUL AS ANTITUMOR AGENTS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 치료제로 사용되는 하기로 이루어진 군으로부터 선택된 화합물:(-)-(4R,4aR,7R,10S,11S,12aR,1Z,5E,8Z)-7,10-에폭시-3,4,4a,7,10,11,12,12a-옥타히드로-7-히드록시-6-(메톡시카르보닐)-1,10,-디메틸-4-(1-메틸에틸)벤조시클로데센-11-일 (E)-3-(1-메틸-1H-이미다졸 4-일)아크릴레이트사르코딕타인A):(-)-(4R,4aR,7R,10S,11S,12aR,1Z,,5E,8Z)-7-10-에폭시-6-(에톡시카르보닐)3,4,4a,7,10,11,12,12a-옥타히드로-7-히드록시-1,10-디메틸-4-(1-메틸에틸)벤조시클로데센-11-일(E)-3-(1-메틸-1H-이미다졸-4-일)아크릴레이트(사르코딕타인 B) : (-)-(3R,4S,4aR,7S,10R,11R,12aS,1Z,5E,8Z)-7,10-에폭시-3,4,4a,7,10,11,12,12a-옥타히드로-3,7-디히드록시-6-(메톡시카르보닐)-1,10-디메틸-4-(1-메틸에틸)벤조시클로데센-11-일 (E)-3-(1-메틸-1H-이미다졸-4-일)아크릴레이트(사르코딕타인 C: (-)-(3R,4S,4aR,7S,10R,11R,12aS,1Z,5E,8Z)-3-아세톡시-7,10-에폭시-3,4,4a,7,10,11,12,12a-옥타히드로-7-히드록시-6-(메톡시카르보닐)-1,10-디메틸-4-(1-메틸에틱)벤조시클로데센-11-일(E)-3-(1-메틸-1H-이미다졸-4-일)아크릴레이트(사르코딕타인D); (+)-(3R,4S,4aR,7S,10R,11R,12aS,1Z,5E,8Z)-7,10-에폭시-3,4,4a,7,10,11,12,12a-옥타히드로-3,7-디히드록시-6-(메톡시카르보닐)-1,10-디메틸-4-(1-메틸에틸)벤조시클로데센-11-일 (Z)-3-1(1-메틸-1H-이미다졸-4-일)아크릴레이트(사르코딕타인 E); 및 (+)-(1R,4R,4aR,7R,10S,11S,12aR,2Z,5E,8Z)-7,10-에폭시-1,4,4a,7,10,11,12,12a-옥타히드로-1,7-디히드록시-6-(메톡시카르보닐)-1,10-디메틸-4-(1-메틸에틸)벤조시클로데센-11-일 (E)-3-(1-메틸-1H-이미다졸-4-일)아크릴레이트(사르코딕타인F).
  2. 제1항에 있어서, 종양 세포중 세포 분할을 현탁시키게 하는 튜불린 조합의 증강제로 사용되는 화합물.
  3. 제1항에 있어서, 항종양제로 사용되는 화합물.
  4. 제1항에 있어서, 화학 치료제에 대하여 내성인 종양의 치료에 사용되는 화합물.
  5. 제4항에 있어서, 화학치료제가 안트라사이클린 글리코시드인 화합물.
  6. 제5항에 있어서, 안트라사이클린 글리코시드가 독소루비신인 화합물.
  7. 인간 또는 동물의 암치료에서 항종양 치료제용 약제의 제조에 사용되는 제1항 기재의 화합물의 용도.
  8. 유효 성분으로서 제1항 기재의 화합물 및 약제학적으로 허용가능한 담체 및/또는 희석제를 함유하는 약제학적 조성물.
  9. 제8항에 있어서, 종양 세포중 세포 분할을 현탁시키게 하는 튜불린 조합의 증강제로 사용되는 약제학적 조성물.
  10. 제8항에 있어서, 인간 또는 동물의 암치료에서 항종양 치료제로 사용되는 제학적 조성물.
  11. 제8항에 있어서, 화학 치료제에 대하여 내성인 종양의 치료에 사용되는 약제학적 조성물.
  12. 제 11항에 있어서, 화학 치료제가 안트라사이클린 글리코시드인 약제학적 조성물.
  13. 제12항에 있어서, 안트라사이클린 글리코시드가 독소루비신인 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970700287A 1995-05-16 1996-04-23 항종양제로서유용한테르페노이딕유도체(사르코딕타인) Expired - Fee Related KR100420018B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9509888.5A GB9509888D0 (en) 1995-05-16 1995-05-16 Terpenoidic derivatives useful as antitumour agents
GB9509888.5 1995-05-16

Publications (2)

Publication Number Publication Date
KR970704436A true KR970704436A (ko) 1997-09-06
KR100420018B1 KR100420018B1 (ko) 2004-05-31

Family

ID=10774540

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970700287A Expired - Fee Related KR100420018B1 (ko) 1995-05-16 1996-04-23 항종양제로서유용한테르페노이딕유도체(사르코딕타인)

Country Status (23)

Country Link
US (2) US5869514A (ko)
EP (1) EP0773782B1 (ko)
JP (1) JPH10503218A (ko)
KR (1) KR100420018B1 (ko)
AT (1) ATE199641T1 (ko)
AU (1) AU717028B2 (ko)
CA (1) CA2194463A1 (ko)
DE (1) DE69612056T2 (ko)
DK (1) DK0773782T3 (ko)
ES (1) ES2159357T3 (ko)
GB (1) GB9509888D0 (ko)
GR (1) GR3035982T3 (ko)
HU (1) HUP9702443A3 (ko)
IL (1) IL118218A (ko)
MX (1) MX9700359A (ko)
NO (1) NO312614B1 (ko)
NZ (1) NZ307540A (ko)
PL (1) PL183644B1 (ko)
PT (1) PT773782E (ko)
RU (1) RU2179441C2 (ko)
UA (1) UA45974C2 (ko)
WO (1) WO1996036335A1 (ko)
ZA (1) ZA963784B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965718A (en) * 1997-10-24 1999-10-12 The Scripps Research Institute Analogs of sarcodictyin and eleutherobin
AU1912299A (en) * 1997-12-11 1999-06-28 Trustees Of Columbia University In The City Of New York, The A synthetic process toward total synthesis of eleutherubin and its analogues nduses thereof
WO1999047154A1 (en) * 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
CA2290316A1 (en) 1999-11-24 2001-05-24 The University Of British Columbia Novel source of eleutherobin and related antimitotic diterpenes
MXPA03003401A (es) * 2000-10-16 2004-06-30 Neopharm Inc Formulacion liposomica de mitoxantrona.
EP1404692A1 (en) * 2001-06-22 2004-04-07 The University of British Columbia Antimitotic eleuthesides
GB0122257D0 (en) * 2001-09-14 2001-11-07 Pharmacia & Upjohn Spa Simplified sarcodictyin derivatives
GB0131034D0 (en) * 2001-12-28 2002-02-13 Pharmacia & Upjohn Spa Benzocyclodecane derivatives with antitumor activity
JP4364554B2 (ja) * 2002-06-07 2009-11-18 株式会社ルネサステクノロジ スイッチング電源装置及びスイッチング電源システム

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861776A (en) * 1987-01-30 1989-08-29 Syntex (U.S.A) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid and derivatives thereof, compositions and use
IL91542A0 (en) * 1988-10-06 1990-04-29 Erba Carlo Spa N-imidazolyl-and n-imidazolyl-methyl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
NO970178L (no) 1997-01-15
PL318130A1 (en) 1997-05-12
WO1996036335A1 (en) 1996-11-21
NZ307540A (en) 1998-02-26
US5869514A (en) 1999-02-09
PT773782E (pt) 2001-08-30
DE69612056T2 (de) 2001-08-23
PL183644B1 (pl) 2002-06-28
AU717028B2 (en) 2000-03-16
EP0773782B1 (en) 2001-03-14
EP0773782A1 (en) 1997-05-21
CA2194463A1 (en) 1996-11-21
RU2179441C2 (ru) 2002-02-20
KR100420018B1 (ko) 2004-05-31
UA45974C2 (uk) 2002-05-15
NO312614B1 (no) 2002-06-10
GR3035982T3 (en) 2001-08-31
DK0773782T3 (da) 2001-06-25
IL118218A0 (en) 1996-09-12
US5922750A (en) 1999-07-13
JPH10503218A (ja) 1998-03-24
GB9509888D0 (en) 1995-07-12
HUP9702443A3 (en) 2000-08-28
DE69612056D1 (de) 2001-04-19
AU5691796A (en) 1996-11-29
ES2159357T3 (es) 2001-10-01
MX9700359A (es) 1997-04-30
ATE199641T1 (de) 2001-03-15
ZA963784B (en) 1997-11-13
IL118218A (en) 1999-10-28
NO970178D0 (no) 1997-01-15
HUP9702443A2 (hu) 1998-06-29

Similar Documents

Publication Publication Date Title
JP2893035B2 (ja) 増強された抗菌剤組成物
JP3260378B2 (ja) 腸感染に対する薬物の調製のためのフマギロールおよびその誘導体の使用
IL127965A0 (en) Pentafluorobenzenesulfonamide derivatives analogs thereof and pharmaceutical compositions containing the same
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
RU94029662A (ru) Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
KR970704436A (ko) 항종양제로서 유용한 테르페노이딕 유도체 (사르코딕타인) (terpenoidic derivatives (sarcodictyins) useful as antitumor agents)
PL321791A1 (en) Method of and compositions and sets of agents for enhancing oral biological availability of pharmaceutic agents
ATE59297T1 (de) Topische antimikrobielle pharmazeutische zusammensetzung enthaltend eine silberverbindung und ein azol.
RU94028670A (ru) Иммунопотенциирующие агенты, способы лечения иммунодефицитных млекопитающих, а также вирусных инфекций и рака у млекопитающих
LU88684I2 (fr) Complexe lipidique d'amphotericine b ainsi que leurs dérivés pharmaceutiquement acceptables (abelcet )
PA8485601A1 (es) Azalidas de 13 miembros y su uso como agentes antibioticos.
RU95110937A (ru) Хинолоновые и акридиноновые соединения, способ их получения, фармацевтическая композиция и промежуточные соединения
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
JPH06500573A (ja) 新規な生物活性ペプチド組成物およびその用途
RU97102163A (ru) Терпеноидные производные, полезные как противоопухолевые агенты
US4450175A (en) Method and compositions for treating acne
AU1556800A (en) Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
RU94046463A (ru) Антиандрогенное соединение, предшественник лекарственного средства, фармацевтические композиции, способ лечения или предотвращения заболеваний
DE59010302D1 (de) R-(-)-1-(5-Hydroxyhexyl)-3-methyl-7-propylxanthin, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel
US3949077A (en) Synergistic antibiotic compositions
MA26744A1 (fr) Polymorphes d'un chlorhydrate d'azo-bicyclo-2,2,2-oct-3-ylamine cristallins et compositions pharmaceutiques les contenant
RU94040865A (ru) Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью
EP1689405B1 (en) Thioridazine and derivatives thereof for reversing anti-microbial drug-resistance
Youssef et al. Studies on Fungus Infection of the External Ear: II. On the Chemotherapy of Otomycosis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20070213

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20070213